BioSpace News Archive

ICON plc reported its financial results for the fourth quarter and year ended December 31, 2023.

Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (“Protagonist” or the “Company”) today announced publication in the New England Journal of Medicine (NEJM) of the REVIVE Phase 2 study (NCT04057040) results evaluating the efficacy and safety of rusfertide in polycythemia vera (PV), a myeloproliferative neoplasm affecting approximately 160,000 patients in the United States (US).

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at Citi’s 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at 8:45 a.m. ET.

PrepMD, as the exclusive sponsor, is thrilled to announce its partnership with MediaSphere and distinguished cardiac professionals, including Beth Davenport and Sallie Gustafson, to present the largest-ever virtual accredited Cardiac Device Clinic Leadership Summit.

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”)'s partner Pfizer Inc. (NYSE: PFE) announced that the European Commission (EC) has granted marketing authorization for VELSIPITY®.

Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on April 26, 2024 to holders of record on March 28, 2024.

Pharmascience Canada is proud to announce the launch of pms-PERINDOPRIL-AMLODIPINE, a drug indicated for the treatment of mild to moderate essential hypertension in adults aged 18 to 65 for whom combination therapy is appropriate.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced the resignation of Dr. Sergio Santillana and the appointment of Dr. Caroline Germa as Chief Medical Officer.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2023 financial results on Wednesday, February 28, 2024.